Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T18:52:16.505Z.
Calculation as of: 2026-10-06T18:52:16.505Z.
Quote observation: 2026-10-06T18:45:30.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a92f25166a0617989281a7eefd332dc08894ee274fcedbd674fe1a92e2c9d78d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$10.41M
EV/Sales Ratio
N/A
TTM Avg
30.14x
3Y Avg
54.00x
5Y Avg
56.96x
Market Cap
$10.45M
EV/Sales Ratio
440.16x
TTM Avg
943.18x
3Y Avg
346.01x
5Y Avg
219.00x
Market Cap
$10.23M
EV/Sales Ratio
N/A
TTM Avg
52.89x
3Y Avg
52.89x
5Y Avg
52.89x
Market Cap
$10.11M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$10.82M
EV/Sales Ratio
7757.35x
TTM Avg
8299.41x
3Y Avg
8299.41x
5Y Avg
8299.41x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Satellos Bioscience Inc. (MSLE) | $10.41M | N/A | N/A | N/A | N/A |
| CytoMed Therapeutics Limited (GDTC)vs › | $10.41M | N/A | 30.14x | 54.00x | 56.96x |
| Senti Biosciences, Inc. (SNTI)vs › | $10.45M | 440.16x | 943.18x | 346.01x | 219.00x |
| Polyrizon Ltd. (PLRZ)vs › | $10.37M | N/A | N/A | N/A | N/A |
| Pluri Inc. (PLUR)vs › | $10.79M | 41.51x | 47.52x | 96.27x | 132.69x |
| Tvardi Therapeutics, Inc. (TVRD)vs › | $10.23M | N/A | 52.89x | 52.89x | 52.89x |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.11M | N/A | N/A | N/A | N/A |
| Lifeward Ltd. (LFWD)vs › | $10.10M | 0.54x | 0.46x | 0.66x | 0.66x |
| Caring Brands, Inc. (CABR)vs › | $10.82M | 7757.35x | 8299.41x | 8299.41x | 8299.41x |
| Valion Bio, Inc. (VBIO)vs › | $9.88M | N/A | 87.23x | 46.21x | 94.29x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
